Sayuri Tanaka1, Ippei Kanazawa2, Masakazu Notsu3, Toshitsugu Sugimoto4. 1. Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan. Electronic address: s-tanaka@med.shimane-u.ac.jp. 2. Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan. Electronic address: ippei.k@med.shimane-u.ac.jp. 3. Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan. Electronic address: mnotsu25@med.shimane-u.ac.jp. 4. Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan. Electronic address: sugimoto@med.shimane-u.ac.jp.
Abstract
OBJECTIVE: The relationship between serum DPP-4 level and visceral fat mass is still unclear in type 2 diabetes mellitus (T2DM). This study thus aimed to examine the association of visceral fat accumulation and metabolic syndrome with serum DPP-4 levels in T2DM. METHODS: Visceral and subcutaneous fat areas were evaluated by performing computed tomography scan in 135 men with T2DM, who had never taken DPP-4 inhibitors or GLP-1 receptor agonists. We investigated the association between serum DPP-4 levels and visceral fat area as well as the presence of metabolic syndrome. RESULTS: Multiple regression analysis adjusted for age, duration of T2DM, body mass index, serum creatinine, and HbA1c showed that serum DPP-4 levels were positively associated with visceral fat area (β=0.25, p=0.04), but not subcutaneous fat area (β=-0.18, p=0.13). In logistic regression analyses adjusted for the confounding factors described above, serum DPP-4 levels were positively associated with visceral fat obesity and metabolic syndrome [odds ratio (OR)=1.63, 95% confidence interval (CI)=1.00-2.66 per standard deviation (SD) increase, p=0.04; OR=1.77, 95%CI=1.09-2.88 per SD increase, p=0.02, respectively]. CONCLUSIONS: The present study showed that serum DPP-4 level was positively and specifically associated with accumulation of visceral fat and the presence of metabolic syndrome in men with T2DM.
OBJECTIVE: The relationship between serum DPP-4 level and visceral fat mass is still unclear in type 2 diabetes mellitus (T2DM). This study thus aimed to examine the association of visceral fat accumulation and metabolic syndrome with serum DPP-4 levels in T2DM. METHODS: Visceral and subcutaneous fat areas were evaluated by performing computed tomography scan in 135 men with T2DM, who had never taken DPP-4 inhibitors or GLP-1 receptor agonists. We investigated the association between serum DPP-4 levels and visceral fat area as well as the presence of metabolic syndrome. RESULTS: Multiple regression analysis adjusted for age, duration of T2DM, body mass index, serum creatinine, and HbA1c showed that serum DPP-4 levels were positively associated with visceral fat area (β=0.25, p=0.04), but not subcutaneous fat area (β=-0.18, p=0.13). In logistic regression analyses adjusted for the confounding factors described above, serum DPP-4 levels were positively associated with visceral fat obesity and metabolic syndrome [odds ratio (OR)=1.63, 95% confidence interval (CI)=1.00-2.66 per standard deviation (SD) increase, p=0.04; OR=1.77, 95%CI=1.09-2.88 per SD increase, p=0.02, respectively]. CONCLUSIONS: The present study showed that serum DPP-4 level was positively and specifically associated with accumulation of visceral fat and the presence of metabolic syndrome in men with T2DM.
Authors: Elizabeth M Rhea; Therese S Salameh; Aric F Logsdon; Angela J Hanson; Michelle A Erickson; William A Banks Journal: AAPS J Date: 2017-04-10 Impact factor: 4.009
Authors: B Sanz; G Larrinaga; A Fernandez-Atucha; J Gil; A B Fraile-Bermudez; M Kortajarena; A Izagirre; P Martinez-Lage; J Irazusta Journal: Heliyon Date: 2018-05-14